Diclofenac Dethyiamine 1.167%w/w Eq. to Diclofenac sodlum 1%w/w + linseed Ol 37%w/w + Methyl Salicylate 10%w/w* Menthol 5%w/w + Capsaicin 0.0257%w/w + Benzyl Alcohol 1%w/w"

Diclofenac Dethyiamine 1.167%w/w Eq. to Diclofenac sodlum 1%w/w + linseed Ol 37%w/w + Methyl Salicylate 10%w/w* Menthol 5%w/w + Capsaicin 0.0257%w/w + Benzyl Alcohol 1%w/w" is a topical formulation formulated with Diclofenac Dethyiamine 1.167%w/w Eq. to Diclofenac sodlum 1%w/w + linseed Ol 37%w/w + Methyl Salicylate 10%w/w* Menthol 5%w/w + Capsaicin 0.0257%w/w + Benzyl Alcohol 1%w/w". The listed active ingredient profile is Diclofenac Dethyiamine w/w . Diclofenac sodlum w/w; linseed Ol w/w; Methyl Salicylate w/w* Menthol w/w; Capsaicin w/w; Benzyl Alcohol w/w", placing the product in the topical analgesic / musculoskeletal category. The formulation contains topical analgesic/counter-irritant ingredients intended for localized musculoskeletal pain relief where appropriate. The dosage form is intended for topical/local application; the exact application site and frequency must follow the approved product instructions. For website cataloguing, the composition, strength, dosage form and formulation characteristics should be displayed prominently and consistently. The product description should remain factual and should not include unapproved cure, superiority, guaranteed-result or broad therapeutic claims. Clinical selection should depend on diagnosis, patient-specific factors, contraindications, concomitant medicines and professional judgement. Prescription status, warnings, interactions, adverse effects and dosing or application instructions must be checked against the current approved product label. Manufacturer, licence, storage, shelf-life, reconstitution where applicable, and market-specific regulatory details should be added only from verified product documentation.